Please login to the form below

Not currently logged in
Email:
Password:

Trophos SA Awarded $1.4mn research grant

Agence Nationale pour la Recherche, the French research agency, has awarded Trophos SA a $1.4mn research grant to support drug development.

Agence Nationale pour la Recherche (ANR), the French research agency, has awarded Trophos SA a $1.4mn research grant to support drug development.

Biopharmaceutical company Trophos SA is currently heading a project into the efficacy of candidate drug TRO40303.

The research project, which is called IRIstop, is hoping to evaluate the ability of TRO40303 to curb cellular damage that occurs in cardiac and cerebral ischemia-reperfusion injury.

CEO at Trophos, Antoine Beret, said: "We are very pleased that the ANR has chosen to support the preclinical and clinical development of TRO40303 as a potential treatment for cardiac and cerebral ischemia-reperfusion injury."

Professor Alain Berdeaux of the University of Creteil's Institut Mondor de Recherche Biomedicale, and Professor Michael Plotkine of the Paris Descartes, Faculte de sciences pharmaceutiques et biologiques will be collaborating on project IRIstop.

Compounds contained within TRO40303 have been found to stimulate function and survival of neurons, cardiomyocytes, and hepatocytes.

Beret said: "This would be the second Trophos product to enter the clinic with a mitochondria-based mechanism of action that is predicted to exhibit a therapeutic benefit in diseases such as neuropathic pain, ischemia-reperfusion injury, and hepatotoxicity."

28th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics